CARDIAC VALVULOTOME MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2024-2031)

Market Size and Trends

The cardiac valvulotome market is estimated to be valued at USD 115.8 Mn in 2024 and is expected to reach USD 157.2 Mn by 2031, exhibiting a compound annual growth rate (CAGR) of 4.5% from 2024 to 2031.

To learn more about this report, request a free sample copy

The cardiac valvulotome market is expected to witness positive growth over the forecast period. This can be attributed to the rising geriatric population worldwide who are more susceptible to cardiac disorders. Additionally, growing awareness about structural heart diseases and availability of more minimally invasive treatment options are further expected to support the market growth. However, risks and complications associated with valvuloplasty procedures and product recalls may hinder the market progress to a certain extent. Overall, innovations to develop safer and more advanced valvulotome technologies will continue driving the market growth during the forecast period.

Growing Geriatric Population

The global population is aging at an increasing rate. According to the UN World Population Prospects report, the number of people aged 65 years and above is projected to grow from 703 million in 2019 to 1.5 billion in 2050. As age advances, the risk of various cardiovascular diseases also rises exponentially. Cardiac issues such as valvular heart diseases are more commonly seen in elderly people. With life expectancy increasing worldwide, the pool of elderly population at risk of developing valvular abnormalities is rising rapidly. This acts as a prominent driver for the cardiac valvulotome market. Manufacturers are developing more advanced valvulotomes catering to the special needs of the geriatric patient group such as those with comorbidities or requiring less invasive procedures.

Market Concentration and Competitive Landscape

To learn more about this report, request a free sample copy

There has been significant progress made in the field of minimal access cardiac surgery. The traditional open-heart surgical techniques for treating valvular diseases are now progressively replacing with minimally invasive or non-invasive endovascular methods. These new procedures are associated with reduced recovery time, lesser post-operative pain and insignificant scarring compared to open-heart surgeries. The availability of innovative cardiac valvulotomes suited for carrying out transcatheter aortic or mitral valve interventions has upscaled the adoption of minimally invasive techniques. Cardiovascular specialists are routinely performing transapical, transfemoral or transaortic valve-in-valve implantations using such advanced valvulotomes. The growing demand for minimally invasive options among healthcare providers as well as patients has been fueling the expansion of the cardiac valvulotome market.

To learn more about this report, request a free sample copy

The cardiac valvulotome market is facing challenges in terms of the adoption of alternative minimally invasive heart valve replacement procedures such as transcatheter aortic valve replacement (TAVR). TAVR procedures are gaining prominence due to benefits such as reduced recovery time and related complications for elderly patients. Additionally, improved technology in terms of valve delivery systems and techniques used in TAVR have increased the viability of such alternative procedures over traditional open-heart surgeries using cardiac valvulotomes.

Market Opportunities – The Development of Advanced Valvulotomes

The development of advanced valvulotomes can indeed present a great opportunity in the cardiac valvulotome market. Valvulotomes are surgical instruments that are used for cutting cardiac valves, particularly for percutaneous valvuloplasty procedures. The current valvulotomes have certain limitations such as lack of precision in cutting, risk of damaging cardiac tissues other than the valve, and difficulty in maneuvering inside the small heart chambers. Developing more advanced valvulotomes that overcome these drawbacks can help facilitate more accurate and safer valve repairs or replacements. Advanced valvulotomes equipped with miniaturized cutting tools, precise articulating mechanisms, real-time imaging and guidance systems may allow for finer, controlled cuts of the valves. This can help interventional cardiologists and cardiac surgeons achieve better clinical outcomes for patients with valve disorders. More targeted and minimally invasive procedures using such valvulotomes may also reduce risks of complications and help faster recovery for patients. By enabling better treatment solutions for heart valve diseases, adoption of new advanced valvulotomes can drive the growth of the cardiac valvulotome market substantially in the coming years.

To learn more about this report, request a free sample copy

The type segment includes expandable cardiac valvulotome and over the wire cardiac valvulotome. The over the wire cardiac valvulotome segment is estimated to hold 52.6% share of the market in 2024 owing to its unique ability to expand and contract during a procedure. This expandability allows surgeons to more easily access narrow vessels and complicated valve structures. Unlike fixed design valvulotomes, expandable versions can conform to different patient anatomies. Their adjustable diameter helps ensure a tight fit in varying valve sizes. This adaptability streamlines the procedure by eliminating the need for multiple tool changes. Surgeons appreciate how expandable valvulotomes simplify sizing and positioning challenges within the heart. Their versatility also expands the eligible patient population. Issues like valve calcification that may preclude use of rigid valvulotomes are less concerning with expandable alternatives. The adjustable fit can still pass through heavily built-up areas. This increases procedural success rates and reduces complications associated with improper sizing. Expandable valvulotomes effectively treat a broader cross-section of patients than fixed alternatives. Their conforming design makes access simple for both routine and complex cases alike.

Insights, By Procedure Type: Increasing Mitral Procedures Drive Volume

The procedure type segment includes valvulotomy, mitral valve commissurotomy, and others. The valvulotomy sub-segment is estimated to hold 41.4% of the market share in 2024 due to the large volume of mitral stenosis cases performed annually. Mitral stenosis, a narrowing of the mitral valve opening between the left atrium and ventricle, remains one of the most common acquired valvular diseases globally. Symptomatic patients often require a valvulotomy to restore valve function.

This robust volume stems from several factors. First, mitral stenosis has a high prevalence related to rheumatic fever propagation in underdeveloped areas. Its chronic nature also ensures a sustained caseload as symptoms progress over many years. Procedural techniques like valvulotomy provide an effective non-surgical option for early-stage cases or inoperable patients. Their minimally invasive nature compared to replacement surgeries further expands appropriate candidacy. Competition from newer procedures is also relatively low compared to other valve diseases. While alternative therapies continue emerging for aortic stenosis, the mitral position is still optimally treated by a carefully-placed valvulotomy in many cases. Surgeons develop sharp skills with this core procedure that maintain its popularity. The long history and understanding of mitral stenosis pathology concentrated the largest portion of valvulotome use here.

Insights, By End User: Hospital Setting Drives Consolidation

The distribution channel segment includes retail pharmacies, hospital pharmacies, e-commerce, and others. The retail pharmacies subsegment is estimated to hold 34.9% of the market share in 2024 in many areas, valvular procedures have increasingly shifted from private physician offices and ambulatory centers into the hospital setting. This centralization occurs for several reasons related to rising acuity and complexity. First, hospitals provide critical infrastructure and facilities to handle complications from valvulotomies and adjust treatment plans accordingly. Their intensive care and emergency response capabilities improve outcomes for high-risk cases. Second, hospitals employ specialized cardiac teams including imaging, anesthesia and nursing staff optimized for structural heart procedures. This multi-disciplinary support streamlines pathways for valvulotomies and enables treating complex multi-valve diseases. Reimbursement pressures also factor into consolidation. Bundled payments reward excellence and volume, favoring larger hospitals demonstrating quality metrics, shortened length of stays and reduced readmissions. Their negotiating clout has concentrated reimbursement as well. Physician preference for hospital employment has removed some lower acuity cases from offices too. With streamlined infrastructure and consolidated purchasing power, hospitals can cost-effectively sustain clinical valvulotome programs at scale. Their dominance will likely persist as treatment complexities continue rising.

Regional Insights

To learn more about this report, request a free sample copy

North America remains the dominant region in the global cardiac valvulotome market and is estimated to hold 46.3% of the market share in 2024. This can be attributed to factors such as the high prevalence of cardiovascular diseases in the U.S. and Canada coupled with advanced healthcare infrastructure and favorable reimbursement policies. Moreover, major market players such as BD, LeMaitre, LimFlow, Inc. have a strong presence and distribution network across the U.S., which has enabled access to technologically advanced valvulotomes. Additionally, North American medical device companies also actively import valvulotomes from established foreign brands and have manufacturing facilities for custom designed valvulotomes. Strict regulations regarding valvulotome approval by the U.S. FDA have maintained quality standards, further cementing the region's prominence.

The Asia Pacific region has emerged as the fastest growing cardiac valvulotome market globally in recent years. Economic development across Southeast Asian nations such as India, China and Japan have led to an increased focus on healthcare. Growing medical tourism along with public-private investments have enhanced surgical capabilities. The rising prevalence of rheumatic heart disease and valvular disorders associated with an aging population in these nations is driving the demand for valvulotomes. Local manufacturers have also strengthened their R&D abilities to design affordable valvulotomes tailored for the Asian cardiac procedures. Further, foreign OEMs are actively engaging in strategic collaborations with regional distributors to expand their market reach across Asia Pacific's price-sensitive territories. The increased affordability of cardiac treatments paired with the presence of skilled cardiac surgeons has propelled the widespread adoption of valvulotomes. Export incentives for medical device components have augmented the valvulotome imports into Asia Pacific nations.

Market Report Scope

Key Developments

• In October 2018, LeMaitre, a provider of devices, implants and services for the treatment of peripheral vascular disease, announced that it had acquired the assets of Cardial, a subsidiary of BD (Becton, Dickinson & Company). Cardial’s product lines, including knitted and woven vascular grafts, valvulotomes and surgical glue, are now available through LeMaitre Vascular.

*Definition: The cardiac valvulotome is a catheter-based controllable surgical instrument used for cutting or disabling the venous valves. Cardiac valvulotome is a key surgical tool used in cardiac valve repair and replacement surgeries. It is a delicate instrument used to cut and remove diseased or damaged heart valves.

Market Segmentation

• Type Insights (Revenue, USD Mn, 2019 - 2031)
  • Expandable Cardiac Valvulotome
  • Over the Wire Cardiac Valvulotome
•  Procedure Type Insights (Revenue, USD Mn, 2019 - 2031)
  • Valvulotomy
  • Mitral Valve Commissurotomy
  • Others
•  End User Insights (Revenue, USD Mn, 2019 - 2031)
  • Hospitals
  • Cardiac Surgery Centers
  • Ambulatory Surgical Centers
  • Others
• Regional Insights (Revenue, USD Mn, 2019 - 2031)
  • North America
    • U.S.
    • Canada
  • Latin America
    • Brazil
    • Argentina
    • Mexico
    • Rest of Latin America
  • Europe
    • Germany
    • U.K.
    • Spain
    • France
    • Italy
    • Russia
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
  • Middle East
    • GCC Countries
    • Israel
    • Rest of Middle East
  • Africa
    • South Africa
    • North Africa
    • Central Africa
• Key Players Insights
  • LeMaitre 
  • INVAMED
  • GeoSurgical
  • LimFlow, Inc.
  • B. Braun SE
  • Teleflex Incorporated
  • StarFish Product Engineering Inc. 
  • Koven Technology Canada Inc.
  • Andramed
  • Zgrum Medical
  • BD
  • PEAK SURGICAL
  • Symmetry Surgical Inc.
  • Procurenet Limited